Werewolf Therapeutics Statistics Share Statistics Werewolf Therapeutics has 44.87M
shares outstanding. The number of shares has increased by 2.68%
in one year.
Shares Outstanding 44.87M Shares Change (YoY) 2.68% Shares Change (QoQ) 0.1% Owned by Institutions (%) 61.23% Shares Floating 33.28M Failed to Deliver (FTD) Shares 32 FTD / Avg. Volume 0.01%
Short Selling Information The latest short interest is 1.04M, so 2.32% of the outstanding
shares have been sold short.
Short Interest 1.04M Short % of Shares Out 2.32% Short % of Float 3.28% Short Ratio (days to cover) 2.72
Valuation Ratios The PE ratio is -0.91 and the forward
PE ratio is -0.7.
Werewolf Therapeutics's PEG ratio is
-0.02.
PE Ratio -0.91 Forward PE -0.7 PS Ratio 34.02 Forward PS 3.2 PB Ratio 0.87 P/FCF Ratio -1.14 PEG Ratio -0.02
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Werewolf Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 7.45,
with a Debt / Equity ratio of 0.51.
Current Ratio 7.45 Quick Ratio 7.45 Debt / Equity 0.51 Debt / EBITDA -0.58 Debt / FCF -0.66 Interest Coverage -15.81
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $40.98K Profits Per Employee $-1.53M Employee Count 46 Asset Turnover 0.01 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -38.54% in the
last 52 weeks. The beta is 0.64, so Werewolf Therapeutics's
price volatility has been higher than the market average.
Beta 0.64 52-Week Price Change -38.54% 50-Day Moving Average 1.24 200-Day Moving Average 1.4 Relative Strength Index (RSI) 42.82 Average Volume (20 Days) 523,704
Income Statement In the last 12 months, Werewolf Therapeutics had revenue of 1.89M
and earned -70.52M
in profits. Earnings per share was -1.63.
Revenue 1.89M Gross Profit 71K Operating Income -73.59M Net Income -70.52M EBITDA -64.05M EBIT -65.86M Earnings Per Share (EPS) -1.63
Full Income Statement Balance Sheet The company has 111M in cash and 37.09M in
debt, giving a net cash position of 73.91M.
Cash & Cash Equivalents 111M Total Debt 37.09M Net Cash 73.91M Retained Earnings -414.59M Total Assets 107.24M Working Capital 82.79M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -56.19M
and capital expenditures -254K, giving a free cash flow of -56.44M.
Operating Cash Flow -56.19M Capital Expenditures -254K Free Cash Flow -56.44M FCF Per Share -1.3
Full Cash Flow Statement Margins Gross margin is 3.77%, with operating and profit margins of -3904.19% and -3740.85%.
Gross Margin 3.77% Operating Margin -3904.19% Pretax Margin -3740.85% Profit Margin -3740.85% EBITDA Margin -3397.61% EBIT Margin -3904.19% FCF Margin -2994.27%
